Phase I/II study to determine the maximum tolerated dose and activity of the combination of romidepsin and carfilzomib in relapsed or refractory peripheral T-cell lymphoma
Latest Information Update: 22 Feb 2023
At a glance
- Drugs Carfilzomib (Primary) ; Romidepsin (Primary)
- Indications Anaplastic large cell lymphoma; Peripheral T-cell lymphoma
- Focus Adverse reactions; Therapeutic Use
- Acronyms RomiCar
- 27 Oct 2021 Status changed from active, no longer recruiting to completed.
- 01 Oct 2021 Status changed from completed to active, no longer recruiting.
- 01 Oct 2021 Planned End Date changed from 1 Jul 2021 to 1 Oct 2021.